Abstract 443TiP
Background
Osteosarcoma is a bone malignancy that occurs primarily in adolescents and young adults. Approximately 30% of patients (pts) with localized disease and 80% of pts with metastatic disease at diagnosis will relapse. Lenvatinib (LEN) is a multikinase inhibitor that directly inhibits tumor growth, and may increase the uptake of chemotherapy into tumor tissue by inhibiting angiogenesis. In a phase I/II study (E7080-G000-207; ITCC-050), LEN (14 mg/m2 dose) + ifosfamide (I) + etoposide (E) demonstrated a PFS rate at 4 months (PFS-4m) of 80% (95% CI: 61–91), with a manageable safety profile in pts with relapsed/refractory osteosarcoma (Gaspar ESMO 2019). This study aims to confirm the activity of LEN + I and E that was observed in the completed phase I/II study.
Trial design
This study will evaluate LEN in combination with I and E in pts (proposed N=72, with randomization of at least 32 pts < 18 yrs old) aged 2 to 25 yrs with confirmed diagnosis of osteosarcoma that is refractory or relapsed following 1-2 prior systemic treatments. Pts previously treated with I and E are eligible, except those with a history of I-related grade ≥ 3 nephrotoxicity or encephalopathy. Randomization will be stratified by time to first relapse/refractory disease (< 18 or ≥ 18 mos) and by age (< 18 or ≥ 18 yrs). Pts in arm A will receive daily oral LEN 14 mg/m2 + I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Pts in arm B will receive I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Treatment will occur in 21-day cycles. The primary objective is PFS-4m by independent imaging review (IIR) using RECIST 1.1 (% of pts alive without progressive disease at week 18). Secondary objectives include PFS, OS, ORR, safety and tolerability, LEN pharmacokinetics characterization in pts in arm A, and quality of life. Tumor assessments will be performed by the investigator every 6 wks. Disease progression must be confirmed by IIR. All AEs will be recorded.
Clinical trial identification
NCT04154189.
Legal entity responsible for the study
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
N. Gaspar: Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy: Ipsen. Q. Campbell-Hewson: Travel/Accommodation/Expenses: Eisai. S.S. Bielack: Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Sensorion; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer Ingelheim; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Loxo. F. Bautista: Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Travel/Accommodation/Expenses: Jazz Pharmaceuticals; Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: EUSA Pharma; Travel/Accommodation/Expenses: Takeda. C. Meazza: Speaker Bureau/Expert testimony: Takeda. K. Janeway: Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Research grant/Funding (institution): Amgen. D.A. Morgenstern: Advisory/Consultancy: Boehringer-Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: Bayer; Research grant/Funding (institution): Bristol-Myers Squibb; Travel/Accommodation/Expenses: EUSA Pharma. L. Dutta, J. McKenzie, K. O'Hara, J. Huang, C.E. Okpara: Full/Part-time employment: Eisai. B. Bidadi: Full/Part-time employment: Merck & Co. Inc.; Shareholder/Stockholder/Stock options: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session